Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
Idowu M, Otieno L, Dumitriu B, Lobo CLC, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Darbari D, Ataga KI, Antmen AB, Kuo KHM, de Souza Medina S, Oluyadi A, Iyer V, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Gheuens S, Smith WR.
Idowu M, et al. Among authors: zaidi au.
Lancet Haematol. 2024 Dec 4:S2352-3026(24)00319-3. doi: 10.1016/S2352-3026(24)00319-3. Online ahead of print.
Lancet Haematol. 2024.
PMID: 39644907